Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ZURAthis companyZura Bio Limited	$0.99	-4.94×	4.86×	0×	-5.6×	-70.8%	0.0%	0.0%	0.0%	-67.6%	-74.1%	-13.2%	0×	1.59×	0×	9.05×	0.0%	2	10.72	1	C-
AARDAardvark Therapeutics, Inc. Common Stock	$1.35	-4.97×	2.69×	0×	-4.17×	71.6%	0.0%	0.0%	0.0%	-54.0%	-58.6%	-18.9%	0×	0.81×	0×	10.61×	0.0%	1	-1.98	3	B-
ARCTArcturus Therapeutics Holdings Inc.	$10.44	-2.55×	0.78×	2.5×	0.61×	-144.1%	95.5%	-111.5%	-97.9%	-30.7%	-31.4%	-44.2%	0.12×	3.28×	0×	6.64×	0.0%	1	-0.72	2	C
ASMBAssembly Biosciences, Inc.	$20.95	-61.84×	1.84×	5.27×	-54.31×	-382.4%	99.8%	-16.8%	-8.5%	-3.0%	-5.8%	-10.8%	0.01×	9.31×	0×	5.22×	0.0%	2	7.22	2	B-
ENTAEnanta Pharmaceuticals, Inc.	$11.49	-3.12×	3.95×	3.91×	-5.99×	-669.1%	93.0%	-130.7%	-125.4%	-126.5%	-31.4%	-12.6%	3.11×	-2.38×	-11.11×	4.21×	0.0%	3	-0.92	1	C-
FHTXFoghorn Therapeutics Inc.	$2.01	-4.58×	-3.13×	11×	-4.24×	-713.4%	89.2%	-265.6%	-240.3%	68.5%	-58.9%	-25.3%	-0.38×	0.56×	0×	2.73×	0.0%	3	-4.44	2	C
Peer median	—	-4.58×	1.84×	3.91×	-4.24×	-382.4%	93.0%	-111.5%	-97.9%	-30.7%	-31.4%	-18.9%	0.01×	0.81×	0×	5.22×	0.0%	2	-0.92	2	—